Bibliography
- Stewart JS , HirdV, SnookD et al.: Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies.Int. J. Radiat. Oncol. Biol. Phys.16 , 405–413 (1989).
- Rosenblum MG , KavanaghJJ, BurkeTW et al.: Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration.J. Natl Cancer Inst.83 , 1629–1636 (1991).
- Buckman R , De Angelis C, Shaw P et al.: Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol. Oncol.47 , 102–109 (1992).
- Crippa F , BolisG, SeregniE et al.: Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18, clinical results in patients with minimal residual disease of ovarian cancer.Eur. J. Cancer31A , 686–690 (1995).
- Mariani G , MoleaN, BacciardiD et al.: Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer.Cancer Res.55 , S5911–S5915 (1995).
- Meredith RF , PartridgeEE, AlvarezRD et al.: Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.J. Nucl. Med.37 , 1491–1496 (1996).
- Laitinen JO , KairemoKJ, JekunenAP, Korppi-TommolaT, TenhunenM: The effect of three dimensional activity distribution on the dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma.Cancer80 , 2545–2552 (1997).
- Juweid M , SharkeyRM, AlaviA et al.: Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.J. Nucl. Med.38 , 257–260 (1997).
- Buijs WC , TibbenJG, BoermanOC et al.: Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration.Eur. J. Nucl. Med.25 , 1552–1561 (1998).
- Rosenblum MG , VerschraegenCF, MurrayJL et al.: Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer, effect of dose and EDTA coadministration on pharmacokinetics and toxicity.Clin. Cancer Res.5 , 953–961 (1999).
- Laitinen JO , TenhunenM, KairemoKJ: Absorbed dose estimates for 131I-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma.Nucl. Med. Commun.21 , 355–360 (2000).
- Alexander C , HolländerM, SchmidtW, KirschCM: Kinetics and dosimetry of monoclonal antibody MAb-170, evaluation of possibilities for intraperitoneal radioimmunotherapy.Nuklearmedizin40 , 207–214 (2001).
- van Zanten-Przybysz I , MolthoffCF, RoosJC et al.: Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18, i.v. vs. i.p.Int. J. Cancer92 , 106–114 (2001).
- Verheijen RH , MassugerLF, BenignoBB et al.: Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.J. Clin. Oncol.24 , 571–578 (2006).
- Andersson H , CederkrantzE, BäckT et al.: Intraperitoneal α-particle radioimmunotherapy of ovarian cancer patients, pharmacokinetics and dosimetry of (211)At-MX35 F(ab‘)2 – a Phase I study.J. Nucl. Med.50 , 1153–1160 (2009).
- Michel RB , CastilloME, AndrewsPM, MattesMJ: In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons.Clin. Cancer Res.10 , 5957–5966 (2004).
- Pouget JP , SantoroL, RaymondL et al.: Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons.Radiat. Res.192–200 (2008).
- Herlyn M , SteplewskiZ, HerlynD, KoprowskiH: Colorectal carcinoma-specific antigen, detection by means of monoclonal antibodies.Proc. Natl Acad. Sci. USA76 , 1438–1442 (1979).
- Boudousq V , RicaudS, GaramboisV et al.: Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.J. Nucl. Med.51 , 1748–1755 (2010).
- Ferris RL , JaffeeEM, FerroneS: Tumor antigen-targeted, monoclonal antibody-based immunotherapy, clinical response, cellular immunity, and immunoescape.J. Clin. Oncol.28 , 4390–4399 (2010).